S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$117.27
+0.29 (+0.25%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$116.81
$117.77
50-Day Range
$88.51
$117.27
52-Week Range
$70.73
$117.77
Volume
1.22 million shs
Average Volume
1.54 million shs
Market Capitalization
$21.75 billion
P/E Ratio
279.21
Dividend Yield
N/A
Price Target
$120.12

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
2.4% Upside
$120.12 Price Target
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.55mentions of BioMarin Pharmaceutical in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$10.38 M Sold Last Quarter
Proj. Earnings Growth
164.77%
From $0.88 to $2.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

191st out of 1,054 stocks

Pharmaceutical Preparations Industry

88th out of 517 stocks


BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update
BioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $132.00
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
6 Analysts Have This to Say About Biomarin Pharmaceutical
Deals, data kick off biotech's big JPM Week
BioMarin Pharmaceutical Inc. (BMRN)
Biotech Stock Finds Favor Among Mutual Fund Managers
BMRN BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical - Solutions For Rare Illnesses
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
10/26/2021
Today
1/29/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,045
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$120.12
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$83.00
Forecasted Upside/Downside
+2.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

Net Income
$-64,080,000.00
Pretax Margin
5.01%

Debt

Sales & Book Value

Annual Sales
$1.85 billion
Cash Flow
$0.86 per share
Book Value
$23.26 per share

Miscellaneous

Free Float
182,228,000
Market Cap
$21.75 billion
Optionable
Optionable
Beta
0.36

Social Links


Key Executives

  • Jean-Jacques BienaiméJean-Jacques Bienaimé
    Chairman & Chief Executive Officer
  • Brian R. MuellerBrian R. Mueller
    Chief Financial Officer & Executive VP-Finance
  • Eduardo E. von Pervieux
    Chief Information Officer
  • Henry J. FuchsHenry J. Fuchs
    President-Worldwide Research & Development
  • Kevin Eggan
    Group VP, Head-Research & Early Development













BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2023?

14 analysts have issued 12-month target prices for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $83.00 to $200.00. On average, they expect the company's stock price to reach $120.12 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN stock has increased by 13.3% and is now trading at $117.27.
View the best growth stocks for 2023 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a decline in short interest in January. As of January 15th, there was short interest totaling 6,700,000 shares, a decline of 35.3% from the December 31st total of 10,360,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the short-interest ratio is presently 4.3 days. Currently, 3.7% of the company's shares are sold short.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biotechnology company earned $408.74 million during the quarter, compared to analyst estimates of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.50% and a net margin of 4.18%. BioMarin Pharmaceutical's quarterly revenue was down 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.47%), Assenagon Asset Management S.A. (0.38%), Scout Investments Inc. (0.30%), DNB Asset Management AS (0.25%), Allspring Global Investments Holdings LLC (0.23%) and Natixis Advisors L.P. (0.03%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $117.27.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $21.75 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,045 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 1/29/2023 by MarketBeat.com Staff